Loading…

Dynamics of Invasive Pneumococcal Disease in Israel in Children and Adults in the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Era: A Nationwide Prospective Surveillance

Abstract Background Following 13-valent pneumococcal conjugate vaccine (PCV13) implementation in infants worldwide, overall and vaccine-type invasive pneumococcal disease (IPD) rates declined in children, with variable indirect impact on adults. Methods A population-based, prospective, nationwide ac...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 2022-05, Vol.74 (9), p.1639-1649
Main Authors: Ben-Shimol, Shalom, Regev-Yochay, Gili, Givon-Lavi, Noga, van der Beek, Bart Adriaan, Brosh-Nissimov, Tal, Peretz, Avi, Megged, Orli, Dagan, Ron
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Following 13-valent pneumococcal conjugate vaccine (PCV13) implementation in infants worldwide, overall and vaccine-type invasive pneumococcal disease (IPD) rates declined in children, with variable indirect impact on adults. Methods A population-based, prospective, nationwide active surveillance of IPD in Israel, 2004–2019 (for adults ≥18 years, 2009–2019). The 7-valent PCV (PCV7)/PCV13 were implemented in Israel in July 2009/November 2010, respectively, with >90% uptake in children 65 years was ~75%. For pre-PCV episodes with missing serotype, extrapolations were applied. Overall, PCV13 serotypes (VT13) and non-VT13 (NVT) incidence rate ratios (IRRs) comparing pre-PCV (2004–2008), early-PCV (2009–2011), and late-PCV13 (2016–2019) periods were calculated for different age groups. Results Overall, 8614 IPD cases were recorded. IPD rates declined by 67% in children
ISSN:1058-4838
1537-6591
DOI:10.1093/cid/ciab645